Parabilis Medicines, Inc. (PBLS)
Nasdaq: PBLS · Pharmaceutical Preparations · filing with the SEC since 2015
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal quarter | Q3 FY26 | Q2 FY26 |
|---|---|---|
| Period ending | Sep 30, 2026 | Jun 30, 2026 |
| Report filed | Nov 12, 2026 | Aug 13, 2026 |
| Revenue | 2,114 | 148 |
| Research and development | 45,597 | 39,377 |
| General and administrative | 11,253 | 11,657 |
| Total operating expenses | 56,850 | 51,034 |
| Operating income | -54,736 | -50,886 |
| Interest expense | 124 | 210 |
| Interest and investment income | 10,369 | 4,189 |
| Total non-operating income (expense) | 10,245 | -1,577 |
| Net income including non-controlling interests | -44,491 | -52,463 |
| Net income | -44,491 | -52,463 |
| Net income to common shareholders | -44,491 | -66,955 |
| Earnings per share, basic | -0.36 | -2.32 |
| Earnings per share, diluted | -0.36 | -2.32 |
| Weighted average shares, basic | 123,593,149 | 28,908,277 |
| Weighted average shares, diluted | 123,593,149 | 28,908,277 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Each quarter is three months. A fourth quarter prints only where the company tagged its three months on their own; the whole year is in the annual view.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding